SCHEMBL2117288

SCHEMBL2117288

Cn1c(C(O)C(F)(F)F)cc(=O)c(O)c1CO

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12949763 0.88 CYP11B2 (0.30) CYP11B2
Hydrochloric Acid SCHEMBL13386437 0.87
SCHEMBL13386402 0.85 ALDH1A1 (0.32)
SCHEMBL2115846 0.83 KDM4E (0.36) CYP11B2
SCHEMBL2116160 0.81 KDM4E (0.32)
SCHEMBL2116339 0.73 COMT (0.37)
SCHEMBL15959301 0.72 ALDH1A1 (0.31)
SCHEMBL12249893 0.72 CYP11B2 (0.32) CYP11B2
SCHEMBL2117504 0.72 CYP11B2 (0.30) CYP11B2
SCHEMBL7554482 0.71 MMP1 (0.40)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2134688-B1 FLUORINATED DERIVATIVES OF DEFERIPRONE APOTEX TECHNOLOGIES INC (CA) 2016-10-05 EP claimed
US-8026261-B2 neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one APOTEX TECHNOLOGIES INC. (CA) 2011-09-27 US claimed
US-9938240-B2 Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX INC. (CA) 2018-04-10 US disclosed
US-9938240-B2 Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX INC. (CA) 2018-04-10 US disclosed
US-9938240-B2 Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX INC. (CA) 2018-04-10 US disclosed
US-20170247329-A1 \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ APOTEX TECHNOLOGIES INC. (CA) 2017-08-31 US disclosed
US-20170247329-A1 \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ APOTEX TECHNOLOGIES INC. (CA) 2017-08-31 US disclosed
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones THE BANK OF NOVA SCOTIA (CA) 2017-03-30 US disclosed
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones THE BANK OF NOVA SCOTIA (CA) 2017-03-30 US disclosed
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones THE BANK OF NOVA SCOTIA (CA) 2017-03-30 US disclosed
US-9550733-B2 Fluorinated derivatives of 3-hydroxypyridin-4-ones APOTEX TECHNOLOGIES INC. (CA) 2017-01-24 US disclosed
US-8673943-B2 Fluorinated derivatives of deferiprone APOTEX TECHNOLOGIES INC. (CA) 2014-03-18 US disclosed
US-20120270882-A1 FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES APOTEX TECHNOLOGIES INC. (CA) 2012-10-25 US disclosed
US-20120270882-A1 FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES APOTEX TECHNOLOGIES INC. (CA) 2012-10-25 US disclosed
US-20120270882-A1 FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES APOTEX TECHNOLOGIES INC. (CA) 2012-10-25 US disclosed
US-20120095061-A1 Fluorinated Derivatives of Deferiprone APOTEX TECHNOLOGIES INC. (CA) 2012-04-19 US disclosed
US-8026261-B2 neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one APOTEX TECHNOLOGIES INC. (CA) 2011-09-27 US disclosed
EP-2134688-A1 FLUORINATED DERIVATIVES OF DEFERIPRONE Apotex Technologies Inc. (CA) 2009-12-23 EP disclosed
WO-2008116301-A1 FLUORINATED DERIVATIVES OF DEFERIPRONE APOTEX TECHNOLOGIES INC. (CA) 2008-10-02 WO disclosed
US-20080242706-A1 Fluorinated derivatives of deferiprone APOTEX TECHNOLOGIES INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242706-A1 Fluorinated derivatives of deferiprone SLC40A1, TFRC, FECH CYP11B2 924/4885
US-20120270882-A1 FLUORINATED DERIVATES OF 3-HYDROXYPYRIDIN-4-ONES FH, FECH, FTH1 CYP11B2 87/4885
US-20120095061-A1 Fluorinated Derivatives of Deferiprone SLC40A1, TFRC, FECH CYP11B2 924/4885
US-20170088518-A1 Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones FH, FECH, FPGS CYP11B2 132/4885
US-20170247329-A1 \"Fluorinated Derivatives of 3-Hydroxypyridin-4-Ones\ FH, FECH, FPGS CYP11B2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.